Impact of Chemotherapy on Symptoms and Symptom Clusters in Postmenopausal Women with Breast Cancer Prior to Aromatase Inhibitor Therapy.

Clics: 293
ID: 28362
2019
Metricas de Calidad y Rendimiento del Articulo
Calidad General
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Evaluacion de Calidad por IA
No analizado
Readership in this journal
Popular

Ranked #27 of 55 articles by views in Journal of clinical nursing

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Resumen
To examine and compare the differences in symptoms and symptom clusters between postmenopausal women with early stage breast cancer who did and did not receive chemotherapy prior to aromatase inhibitor(AI) therapy.Women with breast cancer often experience multiple concurrent symptoms during AI therapy. The burden of symptoms prior to AI are associated with nonadherence to cancer treatment. To date, few studies have comprehensively explored the symptoms and symptom clusters occurring prior to AI therapy.Secondary analysis of a prospective repeated measures study.The sample comprised postmenopausal women (N=339) with breast cancer who would receive AI therapy with or without chemotherapy. We collected information on 48 symptoms after surgery or chemotherapy but before AI therapy using different symptom assessment tools. Mann-Whitney U tests were used to compare the differences in the severity of symptoms between groups. Exploratory factor analysis (EFA) was conducted to determine symptom clusters. This study followed STROBE guidelines.The most severe symptoms among women with breast cancer prior to AI therapy were: breast sensitivity, unhappy with the appearance of my body, general aches and pain, joint pain and muscle stiffness. Women who received chemotherapy prior to AI therapy experienced significantly higher severity of 22 symptoms than women who did not receive chemotherapy. Through EFA seven distinct symptom clusters were revealed in both groups: cognitive, musculoskeletal, psychological, vasomotor, weight, sexual and urinary, with additional gastrointestinal symptom cluster been identified in women who received chemotherapy.This study indicates the presence of symptoms among women with breast cancer prior to AI therapy, with higher severity of symptoms and greater number of symptom clusters for women who received chemotherapy.Nurses should assess and be aware of symptoms and symptom clusters existed prior to AI therapy and manage them in advance. This article is protected by copyright. All rights reserved.
Clave de Referencia
li2019impactjournal Use esta clave para autocitar en el manuscrito mientras usa SciMatic Manuscript Manager o Thesis Manager
Autores Li, Hongjin;Sereika, Susan M;Marsland, Anna L;Conley, Yvette P;Bender, Catherine M;
Revista Journal of clinical nursing
Ano 2019
DOI
10.1111/jocn.15047
URL
Palabras Clave Palabras clave no encontradas

Citas

No se encontraron citas. Para agregar una cita, contacte al administrador en info@scimatic.org

Comentarios

Aun no hay comentarios. Sea el primero en comentar este articulo.